Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
825 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04460911 | Treatment Patterns and Clinical Outcomes Among Patients With HR+/HER2- mBC Receiving Palbociclib Combination Therapy in the US Community Oncology Setting. | completed | — | 317 | PfizerINDUSTRY | 1 | Jan 11, 2024 | clinicaltrials |
| NCT02928224 | Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer(BEACON CRC) | completed | Phase 3 | 702 | Pfizer |
| 27 |
| Dec 21, 2023 |
| clinicaltrials |
| NCT04299048 | Study to Assess the Safety and Tolerability of Repeated Doses of an Investigational New Drug in Patients With Cancer and Cachexia. | completed | Phase 1 | 11 | PfizerINDUSTRY | 1 | Dec 14, 2023 | clinicaltrials |
| NCT03677596 | A Study Of Two Inotuzumab Ozogamicin Doses in Relapsed/ Refractory Acute Lymphoblastic Leukemia Transplant Eligible Patients | completed | Phase 4 | 102 | PfizerINDUSTRY | 8 | Nov 22, 2023 | clinicaltrials |
| NCT04555603 | Axitinib Therapy Management Study | withdrawn | — | 0 | PfizerINDUSTRY | 1 | Nov 21, 2023 | clinicaltrials |
| NCT01774721 | ARCHER1050: A Study of Dacomitinib vs. Gefitinib in 1st-Line Treatment Of Advanced NSCLC. | completed | Phase 3 | 452 | PfizerINDUSTRY | 7 | Nov 14, 2023 | clinicaltrials |
| NCT01934452 | Prospective Observational Analysis Of CR With Sunitinib Treatment In mRCC Patients(APERCU) | completed | — | 77 | PfizerINDUSTRY | 1 | Nov 13, 2023 | clinicaltrials |
| NCT02264665 | OPALINE : A Study Of Morbidity And Mortality At 2 Years(OPALINE) | completed | — | 144 | PfizerINDUSTRY | 1 | Nov 13, 2023 | clinicaltrials |
| NCT02616185 | A Phase 1 Study To Evaluate Escalating Doses Of A Vaccine-Based Immunotherapy Regimen For Prostate Cancer (PrCa VBIR) | terminated | Phase 1 | 91 | PfizerINDUSTRY | 1 | Nov 2, 2023 | clinicaltrials |
| NCT01849874 | A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer | terminated | Phase 3 | 341 | PfizerINDUSTRY | 19 | Oct 30, 2023 | clinicaltrials |
| NCT03330405 | Javelin Parp Medley: Avelumab Plus Talazoparib In Locally Advanced Or Metastatic Solid Tumors | terminated | Phase 1 / Phase 2 | 223 | PfizerINDUSTRY | 9 | Oct 13, 2023 | clinicaltrials |
| NCT04635631 | STUDY OF TALAZOPARIB MONOTHERAPY IN CHINESE PARTICIPANTS WITH ADVANCED SOLID TUMORS | completed | Phase 1 | 15 | PfizerINDUSTRY | 1 | Oct 10, 2023 | clinicaltrials |
| NCT02546375 | A Study To Describe The Real World Use Of Bosutinib In The UK And Netherlands | completed | — | 87 | PfizerINDUSTRY | 1 | Oct 3, 2023 | clinicaltrials |
| NCT03565991 | Javelin BRCA/ATM: Avelumab Plus Talazoparib in Patients With BRCA or ATM Mutant Solid Tumors | terminated | Phase 2 | 202 | PfizerINDUSTRY | 9 | Sep 25, 2023 | clinicaltrials |
| NCT01995513 | Safety Study of Continued Enzalutamide Treatment In Prostate Cancer Patients(PLATO) | completed | Phase 4 | 509 | PfizerINDUSTRY | 11 | Sep 18, 2023 | clinicaltrials |
| NCT02499120 | Safety And Efficacy Study Of Palbociclib Plus Cetuximab Versus Cetuximab To Treat Head And Neck Cancer | completed | Phase 2 | 125 | PfizerINDUSTRY | 15 | Sep 8, 2023 | clinicaltrials |
| NCT03317496 | Safety And Efficacy Study Of Avelumab Plus Chemotherapy With Or Without Other Anti-Cancer Immunotherapy Agents In Patients With Advanced Malignancies | terminated | Phase 1 / Phase 2 | 67 | PfizerINDUSTRY | 8 | Aug 29, 2023 | clinicaltrials |
| NCT05568407 | A Study of Avelumab in Real-World Treatment for Patients With Advanced or Metastatic Urothelial Cancer | terminated | — | 19 | PfizerINDUSTRY | 2 | Jul 13, 2023 | clinicaltrials |
| NCT02584634 | Study to Evaluate Safety, Efficacy, Pharmacokinetics And Pharmacodynamics Of Avelumab In Combination With Either Crizotinib Or PF-06463922 In Patients With NSCLC. (Javelin Lung 101) | terminated | Phase 1 / Phase 2 | 43 | PfizerINDUSTRY | 5 | Jul 7, 2023 | clinicaltrials |
| NCT04230564 | Acute Myeloid Leukemia Real World Treatment Patterns | withdrawn | — | 0 | PfizerINDUSTRY | 0 | Jun 7, 2023 | clinicaltrials |
| NCT03911869 | An Open-Label, Randomized, Multicenter Trial of Encorafenib + Binimetinib Evaluating a Standard-dose and a High-dose Regimen in Patients With BRAFV600-mutant Melanoma Brain Metastasis(POLARIS) | terminated | Phase 2 | 13 | PfizerINDUSTRY | 5 | May 31, 2023 | clinicaltrials |
| NCT00716625 | Special Investigation For Renal Cell Carcinoma (RCC) Of Sunitinib Malate (Regulatory Post Marketing Commitment Plan) | completed | — | 1,674 | PfizerINDUSTRY | 0 | May 3, 2023 | clinicaltrials |
| NCT04396626 | HR+/ HER2- Advanced/ Metastatic Breast Cancer Real World Treatment Patterns and Outcomes | terminated | — | 975 | PfizerINDUSTRY | 1 | Apr 27, 2023 | clinicaltrials |
| NCT03416179 | A Study Evaluating Intensive Chemotherapy With or Without Glasdegib or Azacitidine With or Without Glasdegib In Patients With Previously Untreated Acute Myeloid Leukemia(BRIGHT AML1019) | completed | Phase 3 | 730 | PfizerINDUSTRY | 22 | Apr 21, 2023 | clinicaltrials |
| NCT00716820 | Special Investigation For Gist Of Sunitinib Malate (Regulatory Post Marketing Commitment Plan). | completed | — | 472 | PfizerINDUSTRY | 0 | Apr 6, 2023 | clinicaltrials |
| NCT03642132 | Avelumab and Talazoparib in Untreated Advanced Ovarian Cancer (JAVELIN OVARIAN PARP 100) | terminated | Phase 3 | 79 | PfizerINDUSTRY | 10 | Apr 6, 2023 | clinicaltrials |
| NCT04033991 | Study of Patients With Metastatic and/or Advanced Renal Cell Carcinoma, Treated With Sunitinib/Axitinib. | completed | — | 684 | PfizerINDUSTRY | 1 | Apr 6, 2023 | clinicaltrials |
| NCT04076787 | Clinical Outcomes for Patients With Renal Cell Carcinoma Who Received First-Line Sunitinib | completed | — | 1,769 | PfizerINDUSTRY | 1 | Apr 6, 2023 | clinicaltrials |
| NCT02890368 | Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides | terminated | Phase 1 | 56 | PfizerINDUSTRY | 1 | Apr 5, 2023 | clinicaltrials |
| NCT03878719 | Study of the Combination of Binimetinib and Encorafenib in Adolescent Patients With Unresectable or Metastatic BRAF V600-mutant Melanoma | terminated | Phase 1 | 1 | PfizerINDUSTRY | 1 | Apr 3, 2023 | clinicaltrials |
| NCT03921866 | UK Ibrance Patient Program (IPP) Study(ROIS) | completed | — | 191 | PfizerINDUSTRY | 1 | Mar 17, 2023 | clinicaltrials |
| NCT02776644 | Clinical Outcome Of Advanced Renal Cell Carcinoma In Taiwan | completed | — | 1,349 | PfizerINDUSTRY | 0 | Mar 16, 2023 | clinicaltrials |
| NCT05259397 | PF-07225570 Alone or in Combination With an Anti-PD-1 Antibody in Recurrent Non-muscle Invasive Bladder Cancer (NMIBC) | withdrawn | Phase 1 | 0 | PfizerINDUSTRY | 2 | Mar 8, 2023 | clinicaltrials |
| NCT02609828 | Phase 3 Study on the Efficacy and Safety of Tanezumab in Patients With Cancer Pain Due to Bone Metastasis Who Are Taking Background Opioid Therapy | completed | Phase 3 | 156 | PfizerINDUSTRY | 16 | Feb 16, 2023 | clinicaltrials |
| NCT00585195 | A Study Of Oral PF-02341066, A C-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer(PROFILE 1001) | completed | Phase 1 | 596 | PfizerINDUSTRY | 4 | Feb 8, 2023 | clinicaltrials |
| NCT04456959 | InO - A Retrospective Study of UK Patients With Leukaemia(InO) | completed | — | 28 | PfizerINDUSTRY | 1 | Sep 28, 2022 | clinicaltrials |
| NCT02921919 | Open-Label Extension and Safety Study of Talazoparib | completed | Phase 2 | 120 | PfizerINDUSTRY | 9 | Aug 24, 2022 | clinicaltrials |
| NCT02679755 | Palbociclib In Combination With Letrozole As Treatment Of Post-Menopausal Women With HR+, HER2- Advanced Breast Cancer | completed | Phase 4 | 252 | PfizerINDUSTRY | 2 | Jul 27, 2022 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials